• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Imprivata Partners with Symantec for Comprehensive Fingerprint Biometric & Token Solution for EPCS

by HITC Staff 02/17/2015 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

EPCS-workflow-v9-no-title

Imprivata today announced a partnership with Symantec to provide a comprehensive fingerprint biometric and FICAM-certified Credential Service Provider (CSP) solution for electronic prescribing of controlled substances (EPCS). Symantec Norton Secure Login, acting as the CSP, and Symantec Validation and ID Protection Services (VIP) seamlessly integrate with Imprivata Confirm ID™ to simplify the process of identity-proofing and credentialing prescribers to comply with DEA requirements for EPCS. This gives prescribers the flexibility to use the two-factor authentication options that best fit their organizational e-prescribing requirements.

“Our strategic partnership with Symantec provides customers with a complete, DEA-compliant solution for identity-proofing individual prescribers to help meet regulatory requirements for EPCS. The integrated solution gives administrators a single workflow for enabling the use of Symantec one-time password (OTP) tokens and/or Imprivata’s fingerprint biometric identification for EPCS,” said David Ting, chief technology officer at Imprivata. “This gives hospitals greater flexibility in matching the best two-factor authentication option to fit their prescribers’ clinical workflow requirements.”

The DEA mandates that individual prescribers obtain two-factor authentication credentials from a GSA-approved CSP such as Symantec. The combined Imprivata/Symantec solution gives providers a single, integrated workflow for completing the identity-proofing and credentialing processes, enabling them to use OTP tokens and/or fingerprint biometric identification to meet the two-factor authentication requirements for EPCS.

Imprivata Confirm ID offers provider identity-proofing, supervised enrollment of providers’ approved credentials, support for multiple DEA-approved two-factor authentication modalities for prescription signing, and comprehensive auditing and reporting tools. Imprivata Confirm ID also simplifies EPCS by integrating directly into the e-prescribing workflows of leading EHRs and giving providers the necessary flexibility to leverage the approved two-factor authentication credential options that meet their e-prescribing workflow requirements. This increases efficiency and provider satisfaction while maintaining security, which minimizes the potential for fraud or drug diversion.

“We look forward to working with Imprivata to help customers solve the critical compliance and secure workflow challenges associated with EPCS,” said Dawn Swainston, director, Business Development for Healthcare, Government and Education, Symantec. “We view EPCS as a tremendous market opportunity as organizations look to comply with the rigid security requirements for e-Prescribing, enable secure processes for managing identities and data, and address drug diversion and abuse.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: EPCS, Imprivata

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |